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APPENDIX A 
Serum Protein Estimation Results 
Serum protein content in normotensive rat. 
Sample Protein content (µg) 
NR 1 315.33 ± 0.09 
NR 2 164.00  ± 0.07 
NR 3 220.88  ± 0.08 
 
Serum protein content in nontreated  SHRs. 
Sample Protein content (µg) 
SHR 1 113.95  ± 0.04 
SHR 2 114.80  ± 0.05 
SHR 3 52.13  ± 0.01 
SHR 4 97.63  ± 0.01 
 
Serum protein content in SHR treated with SF extract. 
Sample Protein content (µg) 
SHR-SF 1 208.29  ± 0.12 
SHR-SF 2 273.41  ± 0.12 
SHR-SF 3 343.76  ± 0.08 
SHR-SF 4 204.27  ± 0.08 
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Serum protein content in SHR treated with BL extract. 
Sample Protein content (µg) 
SHR-BL 1 226.77  ± 0.02 
SHR-BL 2 123.97  ± 0.03 
SHR-BL 3 117.31  ± 0.10 
SHR-BL 4 258.38  ± 0.13 
 
 
Serum protein content in SHR treated with Captopril. 
Sample Protein content (µg) 
SHR-Cp 1 377.71 ± 0.03 
SHR-Cp 2 134.40  ± 0.02 
SHR-Cp 3 117.87  ± 0.05 
SHR-Cp 4 301.24  ± 0.07 
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APPENDIX B 
Representative 2-DE gels 
Normotensive rats (NR/SD) 
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APPENDIX C 
2-DE gel calibration curve 
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APPENDIX D 
 Manufacturer protocols (protein estimation) 
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APPENDIX E 
Manufacturer protocol (ZipTip)  
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